AU2002310788B2 - Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists - Google Patents
Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists Download PDFInfo
- Publication number
- AU2002310788B2 AU2002310788B2 AU2002310788A AU2002310788A AU2002310788B2 AU 2002310788 B2 AU2002310788 B2 AU 2002310788B2 AU 2002310788 A AU2002310788 A AU 2002310788A AU 2002310788 A AU2002310788 A AU 2002310788A AU 2002310788 B2 AU2002310788 B2 AU 2002310788B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- lhrh antagonist
- monthly
- treatment
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 206010012289 Dementia Diseases 0.000 title claims abstract description 12
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 10
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 23
- 108700008462 cetrorelix Proteins 0.000 claims abstract description 12
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims abstract description 12
- 229960003230 cetrorelix Drugs 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 3
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 claims description 3
- 108010023617 abarelix Proteins 0.000 claims description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 3
- 229960002184 abarelix Drugs 0.000 claims description 3
- 108010070670 antarelix Proteins 0.000 claims description 3
- 108010083551 iturelix Proteins 0.000 claims description 3
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 3
- 229950011372 teverelix Drugs 0.000 claims description 3
- SMWNCXKOTUSXIC-UHFFFAOYSA-N 1-[7-chloro-3-(3,5-dimethylphenyl)-2-oxo-4-(2-piperidin-2-ylethoxy)-1h-quinolin-6-yl]-3-pyridin-2-ylurea Chemical compound CC1=CC(C)=CC(C=2C(NC3=CC(Cl)=C(NC(=O)NC=4N=CC=CC=4)C=C3C=2OCCC2NCCCC2)=O)=C1 SMWNCXKOTUSXIC-UHFFFAOYSA-N 0.000 claims 2
- NVJDXQUSXGIFBO-UHFFFAOYSA-N pentan-3-yl 2-(2,5-dimethylfuran-3-yl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(2-pyridin-2-ylethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylate Chemical compound C12=NC(C3=C(OC(C)=C3)C)=C(CN(C)CCC=3N=CC=CC=3)N2C(=O)C(C(=O)OC(CC)CC)=CN1CC1=CC=CC=C1F NVJDXQUSXGIFBO-UHFFFAOYSA-N 0.000 claims 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 8
- 108010073521 Luteinizing Hormone Proteins 0.000 description 8
- 229940040129 luteinizing hormone Drugs 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| US60/287,434 | 2001-04-30 | ||
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002310788A1 AU2002310788A1 (en) | 2003-05-15 |
| AU2002310788B2 true AU2002310788B2 (en) | 2007-04-05 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002310788A Ceased AU2002310788B2 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (https=) |
| EP (1) | EP1392348B1 (https=) |
| JP (1) | JP2004529207A (https=) |
| KR (1) | KR20040000446A (https=) |
| CN (1) | CN1317030C (https=) |
| AT (1) | ATE400287T1 (https=) |
| AU (1) | AU2002310788B2 (https=) |
| BG (1) | BG108339A (https=) |
| BR (1) | BR0209290A (https=) |
| CA (1) | CA2444876A1 (https=) |
| CZ (1) | CZ20033167A3 (https=) |
| DE (1) | DE60227507D1 (https=) |
| DK (1) | DK1392348T3 (https=) |
| ES (1) | ES2307760T3 (https=) |
| HU (1) | HUP0400067A2 (https=) |
| IL (1) | IL156777A0 (https=) |
| MX (1) | MXPA03008666A (https=) |
| NO (1) | NO20034322D0 (https=) |
| NZ (1) | NZ544417A (https=) |
| PL (1) | PL362319A1 (https=) |
| PT (1) | PT1392348E (https=) |
| RU (1) | RU2319501C2 (https=) |
| SI (1) | SI1392348T1 (https=) |
| SK (1) | SK14512003A3 (https=) |
| UA (1) | UA80679C2 (https=) |
| WO (1) | WO2002102401A1 (https=) |
| ZA (1) | ZA200305326B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| CN1186326C (zh) | 2000-07-05 | 2005-01-26 | 山之内制药株式会社 | 丙－1,3－二酮衍生物 |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| NZ552372A (en) | 2004-06-04 | 2009-11-27 | Astellas Pharma Inc | Propane-1,3-dione derivative or its salt |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| EP1827468B1 (en) * | 2004-12-23 | 2012-08-22 | Curaxis Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| SI1864976T1 (sl) * | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| AU2007312165A1 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| EP2197469A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| RU2010114025A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
| EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| WO2009145690A1 (en) * | 2008-05-29 | 2009-12-03 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| US6150352A (en) * | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| CA2372044A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| DE60022769T2 (de) | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| WO2001078780A1 (en) | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| CN1186326C (zh) * | 2000-07-05 | 2005-01-26 | 山之内制药株式会社 | 丙－1,3－二酮衍生物 |
-
2002
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322D0/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1317030C (zh) | 2007-05-23 |
| DK1392348T3 (da) | 2008-09-29 |
| CZ20033167A3 (cs) | 2004-08-18 |
| ATE400287T1 (de) | 2008-07-15 |
| NZ544417A (en) | 2008-03-28 |
| MXPA03008666A (es) | 2004-10-15 |
| EP1392348B1 (en) | 2008-07-09 |
| RU2003134949A (ru) | 2005-02-10 |
| IL156777A0 (en) | 2004-02-08 |
| NO20034322L (no) | 2003-09-26 |
| EP1392348A1 (en) | 2004-03-03 |
| SI1392348T1 (sl) | 2008-12-31 |
| PL362319A1 (en) | 2004-10-18 |
| CA2444876A1 (en) | 2002-12-27 |
| BG108339A (bg) | 2004-11-30 |
| CN1575185A (zh) | 2005-02-02 |
| SK14512003A3 (sk) | 2004-08-03 |
| ES2307760T3 (es) | 2008-12-01 |
| UA80679C2 (en) | 2007-10-25 |
| HUP0400067A2 (hu) | 2004-04-28 |
| US7288517B2 (en) | 2007-10-30 |
| BR0209290A (pt) | 2004-07-13 |
| US20020177556A1 (en) | 2002-11-28 |
| NO20034322D0 (no) | 2003-09-26 |
| WO2002102401A1 (en) | 2002-12-27 |
| JP2004529207A (ja) | 2004-09-24 |
| PT1392348E (pt) | 2008-09-09 |
| ZA200305326B (en) | 2003-07-30 |
| HK1072000A1 (en) | 2005-08-12 |
| KR20040000446A (ko) | 2004-01-03 |
| DE60227507D1 (de) | 2008-08-21 |
| RU2319501C2 (ru) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002310788B2 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| EP1663236B1 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| US8921318B2 (en) | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits | |
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| MXPA04009455A (es) | Aumento de produccion endogena de gonadotropina. | |
| TW202332451A (zh) | 手部溼疹之治療 | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| US6437093B1 (en) | Methods of treatment comprising administration of Substance P | |
| JPH09136831A (ja) | 血圧上昇薬 | |
| JPH061721A (ja) | 疼痛処置剤、及び疼痛軽減作用増強剤 | |
| US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
| KR102494794B1 (ko) | 여성 성기능장애의 치료를 위한 약학 조성물 및 방법 | |
| JPH0959149A (ja) | 消炎鎮痛組成物 | |
| CA3191653A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
| JPH04506969A (ja) | 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用 | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| EP1214073A2 (en) | Use of dexrazoxane for treating psoriasis | |
| JPH09136843A (ja) | 血圧上昇薬 | |
| BE737895A (https=) | ||
| HK1090294B (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| JPH07503968A (ja) | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |